Exploring how RNA polymerase I contributes to cell growth and cancer treatment
UNDERSTANDING THE ROLES OF RNA POLYMERASE I IN TRANSCRIPTION AND BEYOND
['FUNDING_OTHER'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11086782
This study is looking at how a special enzyme called RNA polymerase I helps make ribosomal RNA, which is important for cell growth, and by learning more about it, researchers hope to find new ways to stop cancer cells from growing, potentially leading to better treatments for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11086782 on ClinicalTrials.gov |
What this research studies
This research investigates the specific roles of RNA polymerase I in the synthesis of ribosomal RNA, which is crucial for cell growth and proliferation. By understanding how this enzyme functions and its differences from other RNA polymerases, researchers aim to identify new ways to inhibit ribosome synthesis, potentially leading to novel cancer treatments. The study involves biochemical and biophysical analyses to uncover the mechanisms behind RNA polymerase I's activity and its regulation by transcription factors. Patients may benefit from insights gained that could lead to more effective anti-cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals with cancer who are seeking innovative treatment options.
Not a fit: Patients with non-cancerous conditions or those not affected by ribosome synthesis issues may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new anti-cancer therapies targeting ribosome synthesis.
How similar studies have performed: Other research has shown promise in targeting ribosome synthesis as a strategy for cancer treatment, indicating that this approach is both relevant and potentially impactful.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHNEIDER, DAVID ALAN — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: SCHNEIDER, DAVID ALAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, cancer chemotherapy, Cancer Control, Cancer Control Science